Latest News, Press Releases & Events

Spyryx Biosciences to Present Safety, Stability & Effectiveness Data for SPX-101 at the North American CysticFibrosis Conference October 27-29, 2016 Orlando, FL

DURHAM, N.C., Oct. 25, 2016 /PRNewswire/ — Spyryx Biosciences, a clinical-stage biopharmaceuticalcompany developing first-in-class innovative therapeutics to address severe lung diseases, will present three posters (Abstract numbers 222, 257, 289) on the pharmacology, toxicology, manufacturing scale-up and stability of SPX-101, a SPLUNC1-derived peptide that has the potential to provide disease-modifying therapy to all cystic fibrosis […]

Continue Reading

Cystic Fibrosis News Today: Spyryx CEO Talks of Potential of CF Treatment Now Entering Clinical Testing

In Interview, Spyryx CEO Talks of Potential of CF Treatment Now Entering Clinical Testing A preclinical study using animal models of cystic fibrosis (CF) showed that SPX-101, a treatment being developed by Spyryx Biosciences, effectively cleared lung mucus in the animals, regardless of the presence of genetic mutations that promote the development of the disease. […]

Continue Reading

Spyryx Biosciences Presents Development Update at Jefferies Cystic Fibrosis Summit

Spyryx Biosciences Presents Development Update at Jefferies Cystic Fibrosis Summit Progress Shared About Novel, First-In-Class Inhaled Peptide Treatment for Cystic Fibrosis DURHAM, N.C., Oct. 3, 2016 /PRNewswire/ — John Taylor, President and CEO of Spyryx Biosciences, a clinical-stage biopharmaceutical company developing innovative therapeutics to address severe lung diseases, provided an update on the Company’s progress […]

Continue Reading